GSK-1904529A

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameGSK-1904529A

Drug Alias NameIGF-IR tyrosine kinase inhibitor (GlaxoSmithKline)insulin-like growth factor-I receptor tyrosine kinase inhibitor (GlaxoSmithKline)GSK-1904529A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionInsulin-like growth factor I receptor antagonists

TargetsInsulin-like growth factor I receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A